Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
ASPIRING is an investigator-led, multicentre, prospective, randomised, open-label, blind
outcome (PROBE), parallel group, clinical trial. The pilot phase will explore the feasibility
of conducting a trial of starting antiplatelet monotherapy versus avoiding antiplatelet
therapy for reducing all serious vascular events for adults surviving symptomatic stroke due
to spontaneous intracerebral haemorrhage (ICH). The pilot phase will involve ~120 patients at
~30 hospitals in China, Australia and New Zealand.
Phase:
Phase 3
Details
Lead Sponsor:
The George Institute for Global Health, China
Collaborators:
Huashan Hospital The University of Western Australia University of Edinburgh